196 related articles for article (PubMed ID: 30404581)
1. The combination of levomepromazine (methotrimeprazine) and rotigotine enables the safe and effective management of refractory nausea and vomiting in a patient with idiopathic Parkinson's disease.
Hindmarsh J; Hindmarsh S; Lee M; Telford R
Palliat Med; 2019 Jan; 33(1):109-113. PubMed ID: 30404581
[TBL] [Abstract][Full Text] [Related]
2. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.
Sanford M; Scott LJ
CNS Drugs; 2011 Aug; 25(8):699-719. PubMed ID: 21790211
[TBL] [Abstract][Full Text] [Related]
3. Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study.
Sieb JP; Themann P; Warnecke T; Lauterbach T; Berkels R; Grieger F; Lorenzl S
Curr Med Res Opin; 2015 May; 31(5):967-74. PubMed ID: 25772231
[TBL] [Abstract][Full Text] [Related]
4. Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder.
Liguori C; Placidi F; Stefani A; Mercuri NB; Marciani MG; Stanzione P; Pierantozzi M
Parkinsonism Relat Disord; 2015 Dec; 21(12):1476-8. PubMed ID: 26578038
[No Abstract] [Full Text] [Related]
5. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.
Hauser RA; Slawek J; Barone P; Dohin E; Surmann E; Asgharnejad M; Bauer L
BMC Neurol; 2016 Jun; 16():90. PubMed ID: 27267880
[TBL] [Abstract][Full Text] [Related]
6. Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.
Ikeda K; Hirayama T; Takazawa T; Kawabe K; Iwasaki Y
Intern Med; 2016; 55(19):2765-2769. PubMed ID: 27725534
[TBL] [Abstract][Full Text] [Related]
7. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
[TBL] [Abstract][Full Text] [Related]
8. Rotigotine transdermal delivery for the treatment of Parkinson's disease.
Rascol O; Perez-Lloret S
Expert Opin Pharmacother; 2009 Mar; 10(4):677-91. PubMed ID: 19239399
[TBL] [Abstract][Full Text] [Related]
9. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.
Metman LV; Gillespie M; Farmer C; Bibbiani F; Konitsiotis S; Morris M; Shill H; Bara-Jimenez W; Mouradian MM; Chase TN
Clin Neuropharmacol; 2001; 24(3):163-9. PubMed ID: 11391128
[TBL] [Abstract][Full Text] [Related]
10. Rotigotine transdermal patches (Neupro) for the treatment of Parkinson's disease.
Chatsis V
Issues Emerg Health Technol; 2008 Feb; (112):1-6. PubMed ID: 18354859
[No Abstract] [Full Text] [Related]
11. Drug safety evaluation of rotigotine.
Sprenger FS; Seppi K; Poewe W
Expert Opin Drug Saf; 2012 May; 11(3):503-12. PubMed ID: 22468676
[TBL] [Abstract][Full Text] [Related]
12. Effects of the rotigotine transdermal patch versus oral levodopa on swallowing in patients with Parkinson's disease.
Hirano M; Isono C; Fukuda K; Ueno S; Nakamura Y; Kusunoki S
J Neurol Sci; 2019 Sep; 404():5-10. PubMed ID: 31323520
[TBL] [Abstract][Full Text] [Related]
13. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
Perez-Lloret S; Rey MV; Ratti PL; Rascol O
Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
[TBL] [Abstract][Full Text] [Related]
14. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.
Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M
Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100
[TBL] [Abstract][Full Text] [Related]
15. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K; Lyons KE
Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
[TBL] [Abstract][Full Text] [Related]
16. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole.
Giladi N; Boroojerdi B; Korczyn AD; Burn DJ; Clarke CE; Schapira AH;
Mov Disord; 2007 Dec; 22(16):2398-404. PubMed ID: 17935234
[TBL] [Abstract][Full Text] [Related]
17. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
Zareba G
Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
[TBL] [Abstract][Full Text] [Related]
18. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
Splinter MY
Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
[TBL] [Abstract][Full Text] [Related]
19. Spotlight on rotigotine in Parkinson's disease.
Baldwin CM; Keating GM
Drugs Aging; 2008; 25(2):175-7. PubMed ID: 18257604
[TBL] [Abstract][Full Text] [Related]
20. Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
Ceballos-Baumann A; Häck HJ
Curr Med Res Opin; 2011 Oct; 27(10):1899-905. PubMed ID: 21867400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
